4.7 Review

Adult Langerhans Cell Histiocytosis and the Skeleton

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Review Genetics & Heredity

Unusual sites of bone involvement in Langerhans cell histiocytosis: a systematic review of the literature

Nahid Reisi et al.

Summary: Langerhans cell histiocytosis is a rare disease that primarily affects the bone, with rare bone involvement potentially being the first or only symptom of the disease. Diagnosis and treatment of rare bone LCH cases can be challenging, and systemic chemotherapy is often the preferred management approach for multifocal and multisystem cases.

ORPHANET JOURNAL OF RARE DISEASES (2021)

Article Oncology

Discrepancies between F-18-FDG PET/CT findings and conventional imaging in Langerhans cell histiocytosis

Justin Ferrell et al.

Summary: Accurate risk stratification and differentiation of metabolically active from inactive lesions are crucial in managing Langerhans cell histiocytosis (LCH). F-18-FDG PET/CT plays a vital role in detecting LCH lesions not visible on conventional imaging modalities and distinguishing between active and inactive disease. MRI and diagnostic CT remain useful adjunctive tests for identifying CNS and lung lesions.

PEDIATRIC BLOOD & CANCER (2021)

Article Oncology

Histiocytic Neoplasms, Version 2.2021

Ronald S. Go et al.

Summary: Histiocytic neoplasms are rare hematologic disorders, often treated with systemic therapy. For patients with mild disease, observation may be sufficient.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)

Article Oncology

Radiologic findings that aid in the reduction of misdiagnoses of Langerhans cell histiocytosis of the bone: a retrospective study

Mimi Zhao et al.

Summary: In this study, characteristic radiological signs for the diagnosis of Langerhans cell histiocytosis (LCH) of the bone were identified, including skull bone destruction, vertebral collapse, flat and irregular bone osteolysis, and central bone destruction in long bones. These radiological features can help in the early diagnosis of LCH.

WORLD JOURNAL OF SURGICAL ONCOLOGY (2021)

Review Pediatrics

Clinical features and treatment of Langerhans cell histiocytosis

Carlos Rodriguez-Galindo

Summary: Langerhans cell histiocytosis (LCH) is characterized by the expansion of CD1a+/CD207+ cells and is associated with activation of the MAPK signaling pathway. Somatic BRAFV600E mutation is common in LCH, and treatment options range from local therapy to systemic chemotherapy. Survival rates depend on organ dysfunction, with a high risk of disease reactivation even with the use of BRAF or MEK inhibitors.

ACTA PAEDIATRICA (2021)

Editorial Material Oncology

Efficacy ofBRAF-InhibitorTherapy in BRAFV600E-MutatedAdult Langerhans Cell Histiocytosis

Antonious Z. Hazim et al.

ONCOLOGIST (2020)

Article Multidisciplinary Sciences

Efficacy of MEK inhibition in patients with histiocytic neoplasms

Eli L. Diamond et al.

NATURE (2019)

Article Endocrinology & Metabolism

Endocrine manifestations in a cohort of 63 adulthood and childhood onset patients with Langerhans cell histiocytosis

Yempabou Sagna et al.

EUROPEAN JOURNAL OF ENDOCRINOLOGY (2019)

Article Medicine, General & Internal

Diagnosis and treatment of Langerhans Cell Histiocytosis with bone lesion in pediatric patient: A case report

Achmad Fauzi Kamal et al.

ANNALS OF MEDICINE AND SURGERY (2019)

Article Dentistry, Oral Surgery & Medicine

Langerhans cell histiocytosis in an adult with oral cavity involvement: Posing a diagnostic challenge

Richa Nangalia et al.

CONTEMPORARY CLINICAL DENTISTRY (2019)

Article Medicine, General & Internal

Endocrine and metabolic assessment in adults with Langerhans cell histiocytosis

L. Montefusco et al.

EUROPEAN JOURNAL OF INTERNAL MEDICINE (2018)

Review Dermatology

Langerhans cell histiocytosis: A neoplastic disorder driven by Ras-ERK pathway mutations

Gary Tran et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)

Review Endocrinology & Metabolism

Bone metabolism in Langerhans cell histiocytosis

Athanasios D. Anastasilakis et al.

ENDOCRINE CONNECTIONS (2018)

Review Medicine, General & Internal

Periostin: The bone and beyond

L. Idolazzi et al.

EUROPEAN JOURNAL OF INTERNAL MEDICINE (2017)

Article Endocrinology & Metabolism

Low periostin levels in adult patients with Langerhans cell histiocytosis are independently associated with the disease activity

Athanasios D. Anastasilakis et al.

METABOLISM-CLINICAL AND EXPERIMENTAL (2017)

Article Endocrinology & Metabolism

Denosumab for the treatment of adult multisystem Langerhans cell histiocytosis

Polyzois Makras et al.

METABOLISM-CLINICAL AND EXPERIMENTAL (2017)

Article Genetics & Heredity

Vinblastine chemotherapy in adult patients with langerhans cell histiocytosis: a multicenter retrospective study

Abdellatif Tazi et al.

ORPHANET JOURNAL OF RARE DISEASES (2017)

Article Cell Biology

Periostin action in bone

Nicolas Bonnet et al.

MOLECULAR AND CELLULAR ENDOCRINOLOGY (2016)

Article Hematology

Bisphosphonates in Langerhans Cell Histiocytosis: An International Retrospective Case Series

Deepak Chellapandian et al.

MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES (2016)

Article Oncology

Nosology and Pathology of Langerhans Cell Histiocytosis

Jennifer Picarsic et al.

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2015)

Article Endocrinology & Metabolism

Rationale for the Application of RANKL Inhibition in the Treatment of Langerhans Cell Histiocytosis

Polyzois Makras et al.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)

Review Pediatrics

Recent advances in Langerhans cell histiocytosis

Akira Morimoto et al.

PEDIATRICS INTERNATIONAL (2014)

Article Radiology, Nuclear Medicine & Medical Imaging

More than Just Langerhans Cell Histiocytosis: A Radiologic Review of Histiocytic Disorders

Jatin Zaveri et al.

RADIOGRAPHICS (2014)

Article Endocrinology & Metabolism

Serum Osteoprotegerin, RANKL, and Dkk-1 Levels in Adults with Langerhans Cell Histiocytosis

Polyzois Makras et al.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)

Article Oncology

Reduced bone mineral density in adult patients with Langerhans cell histiocytosis

Polyzois Makras et al.

PEDIATRIC BLOOD & CANCER (2012)

Article Multidisciplinary Sciences

Optimal Therapy for Adults with Langerhans Cell Histiocytosis Bone Lesions

Maria A. Cantu et al.

PLOS ONE (2012)

Article Multidisciplinary Sciences

Langerhans cells down-regulate inflammation-driven alveolar bone loss

Moran Arizon et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)

Article Endocrinology & Metabolism

Skeletal Diseases in Cushing's Syndrome: Osteoporosis versus Arthropathy

Gregory Kaltsas et al.

NEUROENDOCRINOLOGY (2010)

Article Endocrinology & Metabolism

Cellular mechanisms for methotrexate chemotherapy-induced bone growth defects

Cory J. Xian et al.

Review Endocrinology & Metabolism

Endocrine manifestations in Langerhans cell histiocytosis

Polyzois Makras et al.

TRENDS IN ENDOCRINOLOGY AND METABOLISM (2007)

Review Hematology

Cutaneous langerhans cell sarcoma:: A case report and review of the literature

Olga L. Bohn et al.

INTERNATIONAL JOURNAL OF HEMATOLOGY (2007)